Prestige Pulls Trastuzumab After EMA Knockback
Formal Withdrawal Of MAA Follows CHMP Negative Opinion And Re-Examination
Executive Summary
Prestige Biopharma has formally withdrawn its marketing authorization application for its Tuznue (trastuzumab) biosimilar candidate, following a negative opinion from the EMA’s CHMP as well as a requested re-examination.